GCP
ZURA icon

GSA Capital Partners’s Zura Bio ZURA Stock Holding History

GSA Capital Partners’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,702
Closed -$29K – 2214
2025
Q1 		$29K Buy
22,702
+12,150
+115% +$19.2K ﹤0.01% 1573
2024
Q4 		$26K Buy
+10,552
New +$37.6K ﹤0.01% 1552

Other funds holding ZURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

GSA Capital Partners's ZURA Position: Q2 2025 in Review

GSA Capital Partners sold out of Zura Bio (ZURA) in Q2 2025, closing a stake of 22,702 shares — an estimated $29K sold.

GSA Capital Partners first reported a position in ZURA in Q4 2024 and held it in 2 quarters. The position peaked at $29K in Q1 2025. 65 funds tracked by Wall St. Rank hold ZURA as of Q2 2025.

  • GSA Capital Partners reported no remaining Zura Bio position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 22,702 Zura Bio shares in Q2 2025, an estimated $29K.
  • GSA Capital Partners first reported a position in Zura Bio in Q4 2024 and held it in 2 quarters.
  • GSA Capital Partners's Zura Bio position peaked at $29K in Q1 2025.
  • 65 funds tracked by Wall St. Rank held Zura Bio as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.